In Vitro Assessment of the Allelic Variants of Cytochrome P450

被引:104
作者
Hiratsuka, Masahiro [1 ]
机构
[1] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pharmacotherapy Life Style Related Dis, Aoba Ku, Sendai, Miyagi 9808578, Japan
基金
日本学术振兴会;
关键词
cytochrome P450; pharmacogenetics; genetic polymorphism; SNP; allelic variant; in vitro; kinetic parameter; POOR METABOLIZER PHENOTYPE; POTENTIALLY DEFECTIVE ALLELES; HUMAN LIVER-MICROSOMES; ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; CATALYTIC-ACTIVITY; JAPANESE POPULATION; SACCHAROMYCES-CEREVISIAE; SPECTRAL CHARACTERIZATION; S-MEPHENYTOIN;
D O I
10.2133/dmpk.DMPK-11-RV-090
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The cytochrome P450 (CYP) superfamily is one of the most important groups of enzymes involved in drug metabolism. It is responsible for the metabolism of a large number of drugs. Many CYP isoforms are expressed polymorphically, and catalytic alterations of allelic variant proteins can affect the metabolic activities of many drugs. The CYP2D6, CYP2C9, CYP2C19, and CYP2B6 genes are particularly polymorphic, whereas CYP1A1, CYP1A2, CYP2E1, and CYP3A4 are relatively well conserved without common functional polymorphisms. In vitro studies using cDNA expression systems are useful tools for evaluating functional alterations of the allelic variants of CYP, particularly for low-frequency alleles. Recombinant CYPs have been successfully expressed in bacteria, yeast, baculoviruses, and several mammalian cells. Determination of CYP variant-mediated kinetic parameters (K-m and V-max) in vitro can be useful for predicting drug dosing and clearance in humans. This review focuses on the advantages and disadvantages of the various cDNA-expression systems used to determine the kinetic parameters for CYP allelic variants, the methods for determining the kinetic parameters, and the findings of in vitro studies on highly polymorphic CYPs, including CYP2D6, CYP2C9, CYP2C19, and CYP2B6.
引用
收藏
页码:68 / 84
页数:17
相关论文
共 109 条
[1]
Functional analysis of CYP2D6.31 variant:: Homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution [J].
Allorge, D ;
Bréant, D ;
Harlow, J ;
Chowdry, J ;
Lo-Guidice, JM ;
Chevalier, D ;
Cauffiez, C ;
Lhermitte, M ;
Blaney, FE ;
Tucker, GRT ;
Broly, F ;
Ellis, SW .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2005, 59 (02) :339-346
[2]
In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism [J].
Allorge, D ;
Harlow, J ;
Boulet, O ;
Hayhurst, GP ;
Chowdry, J ;
Roth, E ;
Crewe, K ;
Lo-Guidice, JM ;
Lhermitte, M ;
Broly, F ;
Tucker, GT ;
Ellis, SW .
PHARMACOGENETICS, 2001, 11 (08) :739-741
[3]
NOVEL EXOGENOUS HEME-DEPENDENT EXPRESSION OF MAMMALIAN CYTOCHROME-P450 USING BACULOVIRUS [J].
ASSEFFA, A ;
SMITH, SJ ;
NAGATA, K ;
GILLETTE, J ;
GELBOIN, HV ;
GONZALEZ, FJ .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1989, 274 (02) :481-490
[4]
The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant -: Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations [J].
Bapiro, TE ;
Hasler, JA ;
Ridderström, M ;
Masimirembwa, CM .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (09) :1387-1398
[5]
EXPRESSION AND ENZYMATIC-ACTIVITY OF RECOMBINANT CYTOCHROME-P450 17-ALPHA-HYDROXYLASE IN ESCHERICHIA-COLI [J].
BARNES, HJ ;
ARLOTTO, MP ;
WATERMAN, MR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (13) :5597-5601
[6]
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[7]
Identification and functional characterization of new potentially defective alleles of human CYP2C19 [J].
Blaisdell, J ;
Mohrenweiser, H ;
Jackson, J ;
Ferguson, S ;
Coulter, S ;
Chanas, B ;
Xi, T ;
Ghanayem, B ;
Goldstein, JA .
PHARMACOGENETICS, 2002, 12 (09) :703-711
[8]
Discovery of new potentially defective alleles of human CYP2C9 [J].
Blaisdell, J ;
Jorge-Nebert, LF ;
Coulter, S ;
Ferguson, SS ;
Lee, SJ ;
Chanas, B ;
Xi, T ;
Mohrenweiser, H ;
Ghanayem, B ;
Goldstein, JA .
PHARMACOGENETICS, 2004, 14 (08) :527-537
[9]
CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin [J].
Bland, TM ;
Haining, RL ;
Tracy, TS ;
Callery, PS .
BIOCHEMICAL PHARMACOLOGY, 2005, 70 (07) :1096-1103
[10]
Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles [J].
Bogni, A ;
Monshouwer, M ;
Moscone, A ;
Hidestrand, M ;
Ingelman-Sundberg, M ;
Hartung, T ;
Coecke, S .
TOXICOLOGY IN VITRO, 2005, 19 (05) :621-629